株式会社グローバルインフォメーション
TEL: 044-952-0102
表紙
市場調査レポート

大手製薬会社の各種提携契約:取引動向・関連企業・財務条件

Global Big Pharma Partnering Terms and Agreements 2014-2019: Deal trends, players and financials

発行 Current Partnering, a division of Wildwood Ventures Limited 商品コード 244587
出版日 ページ情報 英文 1500+ Pages
納期: 即日から翌営業日
価格
本日の銀行送金レート: 1USD=109.13円で換算しております。
Back to Top
大手製薬会社の各種提携契約:取引動向・関連企業・財務条件 Global Big Pharma Partnering Terms and Agreements 2014-2019: Deal trends, players and financials
出版日: 2019年09月01日 ページ情報: 英文 1500+ Pages
概要

当レポートでは、世界の大手製薬会社の各種提携契約について調査し、近年の提携契約の動向、取引タイプ・治療分野・技術など各種区分別の内訳、提携契約の財務条件、主な大型契約、提携契約に積極的な企業、主要企業のプロファイルなどをまとめています。

エグゼクティブサマリー

第1章 イントロダクション

第2章 医薬品大手の各種契約動向

  • イントロダクション
  • 過去の提携動向
  • 提携活動にもっとも活発な事業者
  • 提携動向:取引タイプ別
  • 提携動向:治療分野別
  • 提携動向:取引タイプ別
  • 提携動向:技術タイプ別
  • 提携契約条件
    • 契約総額
    • 前払い金
    • マイルストーン (目標到達毎) 支払い金
    • ロイヤルティレート

第3章 主要契約

  • イントロダクション
  • 主要契約:契約額別

第4章 もっとも活発な事業者

  • イントロダクション
  • もっとも活発な事業者
  • 提携企業の企業プロファイル
    • Pfizer
    • Sanofi
    • Abbott
    • GlaxoSmithKline
    • Johnson & Johnson、など

第5章 医薬品大手による契約:ディレクトリ

第6章 医薬品大手による契約:技術タイプ別

第7章 提携リソースセンター

  • オンライン
  • イベント
  • 参考文献

付録

図表

目次
Product Code: CP1010

Provides a detailed understanding and analysis of how and why companies enter Big Pharma partnering deals.

Benefits

‘Global Big Pharma Partnering Terms and Agreements 2014 to 2019 report’ provides a detailed understanding and analysis of how and why companies enter Big Pharma partnering deals. These deals tend to be multicomponent, starting with collaborative R&D, and proceed to commercialization of outcomes.

This report provides details of the latest Big Pharma agreements announced in the life sciences since 2014.

The report takes the reader through a comprehensive review Big Pharma deal trends, key players, top deal values, as well as deal financials, allowing the understanding of how, why and under what terms, companies are entering Big Pharma partnering deals.

The report presents financial deal term values for Big Pharma deals, listing by headline value, upfront payments, milestone payments and royalties, enabling readers to analyse and benchmark the financial value of deals.

The middle section of the report explores the leading dealmakers in the Big Pharma partnering field; both the leading deal values and most active Big Pharma dealmaker companies are reported allowing the reader to see who is succeeding in this dynamic dealmaking market.

One of the key highlights of the report is that over 2,600 online deal records of actual Big Pharma deals, as disclosed by the deal parties, are included towards the end of the report in a directory format - by company A-Z, stage of development, deal type, therapy focus, and technology type - that is easy to reference. Each deal record in the report links via Weblink to an online version of the deal.

In addition, where available, records include contract documents as submitted to the Securities Exchange Commission by companies and their partners. Whilst many companies will be seeking details of the payment clauses, the devil is in the detail in terms of how payments are triggered - contract documents provide this insight where press releases and databases do not.

The initial chapters of this report provide an orientation of Big Pharma dealmaking. Chapter 1 provides an introduction to the report, whilst chapter 2 provides an overview of the trends in Big Pharma dealmaking since 2014, including details of headline, upfront, milestone and royalty terms.

Chapter 3 provides a review of the leading Big Pharma deals since 2014. Deals are listed by headline value. Where the deal has an agreement contract published at the SEC a link provides online access to the contract.

Chapter 4 provides a comprehensive listing of the top 25 most active companies including Pfizer, Sanofi, Abbott, GlaxoSmithKline, Johnson & Johnson and many others, in Big Pharma dealmaking with a brief summary followed by a comprehensive listing of Big Pharma deals announded by that company, as well as contract documents, where available.

Chapter 5 provides a comprehensive and detailed review of Big Pharma partnering deals signed and announced since Jan 2014, where a contract document is available in the public domain. Each deal title links via Weblink to an online version of the deal record and contract document, providing easy access to each contract document on demand.

Chapter 6 provides a comprehensive and detailed review of Big Pharma partnering deals signed and announced since Jan 2014. The chapter is organized by specific technology type. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each deal on demand.

A comprehensive series of appendices is provided organized by Big Pharma partnering company A-Z, stage of development, deal type, and therapy focus. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each deal on demand.

The report also includes numerous tables and figures that illustrate the trends and activities in Big Pharma partnering and dealmaking since 2014.

In conclusion, this report provides everything a prospective dealmaker needs to know about partnering in the research, development and commercialization of Big Pharma technologies and products.

Key benefits

‘Global Big Pharma Partnering 2014-2019: Deal trends, players, financials and forecasts’ provides the reader with the following key benefits:

  • In-depth understanding of Big Pharma deal trends since 2014
  • Access to headline, upfront, milestone and royalty data
  • Analysis of the structure of Big Pharma agreements with real life case studies
  • Detailed access to actual Big Pharma contracts entered into by leading biopharma companies
  • Identify most active Big Pharma dealmakers since 2014
  • Insight into terms included in a Big Pharma partnering agreement, with real world examples
  • Understand the key deal terms companies have agreed in previous deals
  • Undertake due diligence to assess suitability of your proposed deal terms for partner companies

Report scope

‘Global Big Pharma Partnering 2014-2019: Deal trends, players, financials and forecasts’ is intended to provide the reader with an in-depth understanding and access to Big Pharma trends and structure of deals entered into by leading companies worldwide.

‘Big Pharma Partnering Terms and Agreements’ includes:

  • Trends in Big Pharma dealmaking in the biopharma industry since 2014
  • Analysis of Big Pharma deal structure
  • Access to headline, upfront, milestone and royalty data
  • Case studies of real-life Big Pharma deals
  • Access to Big Pharma contract documents
  • Leading Big Pharma deals by value since 2014
  • Most active Big Pharma dealmakers since 2014

In ‘Global Big Pharma Partnering 2014-2019: Deal trends, players, financials and forecasts’, the available deals are listed by:

  • Company A-Z
  • Headline value
  • Stage of development at signing
  • Deal component type
  • Specific therapy target
  • Technology type

Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

‘The Global Big Pharma Partnering 2014-2019: Deal trends, players, financials and forecasts’ report provides comprehensive access to available deals and contract documents for over 2,600 Big Pharma deals.

Analyzing actual contract agreements allows assessment of the following:

  • What are the precise rights granted or optioned?
  • What is actually granted by the agreement to the partner company?
  • What exclusivity is granted?
  • What is the payment structure for the deal?
  • How aresalesand payments audited?
  • What is the deal term?
  • How are the key terms of the agreement defined?
  • How are IPRs handled and owned?
  • Who is responsible for commercialization?
  • Who is responsible for development, supply, and manufacture?
  • How is confidentiality and publication managed?
  • How are disputes to be resolved?
  • Under what conditions can the deal be terminated?
  • What happens when there is a change of ownership?
  • What sublicensing and subcontracting provisions have been agreed?
  • Which boilerplate clauses does the company insist upon?
  • Which boilerplate clauses appear to differ from partner to partner or deal type to deal type?
  • Which jurisdiction does the company insist upon for agreement law?

Table of Contents

Executive Summary

Chapter 1 - Introduction

Chapter 2 - Trends in Big Pharma dealmaking

  • 2.1. Introduction
  • 2.2. Big Pharma partnering over the years
  • 2.3. Most active Big Pharma dealmakers
  • 2.4. Big Pharma partnering by deal type
  • 2.5. Big Pharma partnering by therapy area
  • 2.6. Big Pharma partnering by technology type
  • 2.7. Deal terms for Big Pharma partnering
    • 2.7.1. Big Pharma partnering headline values
    • 2.7.2. Big Pharma deal upfront payments
    • 2.7.3. Big Pharma deal milestone payments
    • 2.7.4. Big Pharma royalty rates

Chapter 3 - Leading Big Pharma deals

  • 3.1. Introduction
  • 3.2. Top Big Pharma deals by value

Chapter 4 - Most active Big Pharma dealmakers

  • 4.1. Introduction
  • 4.2. Most active Big Pharma dealmakers
  • 4.3. Most active Big Pharma partnering company profiles
  • Including Pfizer, Sanofi, Abbott, GlaxoSmithKline, Johnson & Johnson and many others

Chapter 5 - Big Pharma contracts dealmaking directory

  • 5.1. Introduction
  • 5.2. Big Pharma contracts dealmaking directory

Chapter 6 - Big Pharma dealmaking by technology type

Chapter 7 - Partnering resource center

  • 7.1. Online partnering
  • 7.2. Partnering events
  • 7.3. Further reading on dealmaking

Appendices

  • Appendix 1 - Big Pharma deals by company A-Z
  • Appendix 2 - Big Pharma deals by stage of development
  • Appendix 3 - Big Pharma deals by deal type
  • Appendix 4 - Big Pharma deals by therapy area
  • Appendix 5 - Deal type definitions

About Wildwood Ventures

  • Current Partnering
  • Current Agreements
  • Recent report titles from Current Partnering

Table of figures

  • Figure 1: Big Pharma partnering since 2014
  • Figure 2: Active Big Pharma dealmaking activity since 2019
  • Figure 3: Big Pharma partnering by deal type since 2014
  • Figure 4: Big Pharma partnering by disease type since 2014
  • Figure 5: Big Pharma partnering by technology type since 2014
  • Figure 6: Big Pharma deals with a headline value
  • Figure 7: Big Pharma deals with an upfront value
  • Figure 8: Big Pharma deals with a milestone value
  • Figure 9: Big Pharma deals with a royalty rate value
  • Figure 10: Top Big Pharma deals by value since 2014
  • Figure 11: Most active Big Pharma dealmakers since 2014
  • Figure 12: Online partnering resources
  • Figure 13: Forthcoming partnering events
Back to Top